IL-2 muteins and uses thereof
The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
1. A method of treating a condition selected from the group consisting of atopic dermatitis, and Systemic Lupus Erythematosus (SLE), in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a polypeptide comprising an amino acid sequence of SEQ ID NO: 27, and a pharmaceutically acceptable carrier.
2. The method of claim 1 , wherein the polypeptide further comprises an Fc region.
3. The method of claim 2 , wherein the Fc region comprises an amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 15.
4. The method of claim 2 , wherein the Fc region is linked at the C-terminus of the amino acid sequence of SEQ ID NO: 27.
5. The method of claim 2 , wherein the Fc region is linked at the N-terminus of the amino acid sequence of SEQ ID NO: 27.
6. The method of claim 2 , wherein the polypeptide further comprises a linker peptide that links the amino acid sequence of SEQ ID NO: 27 and the Fc region.
7. The method of claim 6 , wherein the linker peptide comprises an amino acid sequence of (GGGGS)n, wherein n is 1, 2, 3, or 4.
8. The method of claim 7 , wherein n is 4.
9. The method of claim 8 , wherein the Fc region comprises the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 15.
10. The method of claim 9 , wherein the linker peptide links the Fc region to the C-terminus of the amino acid sequence of SEQ ID NO: 27.
11. The method of claim 9 , wherein the linker peptide links the Fc region to the N-terminus of the amino acid sequence of SEQ ID NO: 27.
12. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 40.
13. The method of claim 1 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 40.
14. The method of claim 1 , wherein the pharmaceutical composition comprises a dimer of polypeptides each comprising the amino acid sequence of SEQ ID NO-40.
15. The method of claim 1 , wherein the pharmaceutical composition comprises a dimer of polypeptides each consisting of the amino acid sequence of SEQ ID NO:40.
16. The method of claim 1 , wherein the condition is atopic dermatitis.
17. The method of claim 1 , wherein the condition is SLE.
18. A method of treating a condition selected from atopic dermatitis, and Systemic Lupus Erythematosus (SLE), in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a polypeptide comprising an amino acid sequence of SEQ ID NO: 40, and a pharmaceutically acceptable carrier.
19. The method of claim 18 , wherein the pharmaceutical composition comprises a dimer of polypeptides each comprising the amino acid sequence of SEQ ID NO:40.
20. The method of claim 18 , wherein the pharmaceutical composition comprises a dimer of polypeptides each consisting of the amino acid sequence of SEQ ID NO:40.
21. The method of claim 18 , wherein the condition is atopic dermatitis.
22. The method of claim 18 , wherein the condition is SLE.